What Raziel Therapeutics does

Raziel Therapeutics is an Israel-based clinical-stage pharmaceutical company developing RZL-012 (also known as Tapencarium or Utenpanium), a proprietary injectable fat-dissolving small molecule for focal fat reduction. The compound is administered as a single, non-surgical treatment and is being evaluated across three indications: submental fat (double chin), body contouring (flanks), and Dercum's disease (painful lipomatosis). Clinical evidence has been published in Dermatologic Surgery (2021) and Aesthetic Surgery Journal (2023), documenting mechanism of action and efficacy/safety in submental fat reduction.

The company has built its pipeline to Phase 3 readiness in China via a commercial licensing agreement with Fosun Pharma (through its JuveStar affiliate), with a Phase 3 registration trial for submental fat initiated in 2025. In the US, Raziel has completed an End of Phase 2 meeting with the FDA for the submental fat indication and is targeting a 2027 US launch. The flanks/body contouring program has produced proof-of-concept clinical data (presented at ISAPS 2023), and the Dercum's disease program has published clinical results. The firm has not yet commercialized any product; the stated revenue model is licensing royalties, with Fosun Pharma representing the only disclosed commercial anchor.

Raziel serves aesthetic patients seeking non-surgical focal fat reduction as its primary segment, plus a secondary segment of Dercum's disease patients. The leadership team includes CEO and founder Alon Bloomenfeld (ex-CFO of Collplant and other public/private companies), Chairman Philippe Schaison (former Allergan US Aesthetic & Dermatology President), and CMO Patricia Walker (former CSO of Allergan Medical Aesthetics and CMO of Kythera, which brought Kybella to market), giving the company deep aesthetics-pharma operational credibility relative to its 1-10 employee headcount. The company is privately held, incorporated and operating from Israel (Rehovot and Hod Hasharon), with no parent company or public listing disclosed.

Name

Raziel Therapeutics

Legal name

Raziel Therapeutics

Website

https://Raziel-therapy.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Short description

Raziel Therapeutics is an Israel-based clinical-stage pharmaceutical company developing RZL-012, a proprietary single-session injectable fat-dissolving compound targeting submental fat, body contouring, and Dercum's disease, with a China licensing deal with Fosun Pharma and an FDA-cleared Phase 2 milestone.

Ownership category

akta.pro rank

Product category

Aesthetic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Dermatology Specialty Pharmaceuticals (HLAIACAL)

Keywords

• Focal fat reduction
• Injectable aesthetics
• Aesthetic pharmaceuticals
• Clinical stage biopharma
• Fat dissolution therapy

Headquarters

HQ city

Rehovot

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Licensing Royalties: Commercial licensing agreements for product distribution in specific geographic markets. The company has signed a commercial licensing agreement with Fosun Pharma for the Chinese market covering submental fat applications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Raziel Therapeutics develops RZL-012 (Utenpanium/Tapencarium), a proprietary fat-dissolving injectable compound intended as a single-session, non-surgical therapy for focal fat reduction. The compound is being clinically advanced across three indications: submental fat (double chin) reduction, body contouring of the flanks, and treatment of Dercum's Disease. Commercialization is pursued via licensing agreements, with Fosun Pharma licensed for the Chinese market.

Product overview

Raziel Therapeutics offers a single proprietary injectable compound (RZL-012, also known as Utenpanium or Tapencarium) for focal fat reduction. The core product is a one-time, non-surgical fat-dissolving injection that addresses three main applications: Submental Fat (double chin), Body Contouring/Flanks, and Dercum's Disease. The company is advancing this compound through clinical development phases, with submental fat treatment in Phase 3 registration trial in China and having completed FDA End of Phase 2 meeting. Commercial licensing agreement has been signed with Fosun Pharma for the Chinese market.

Differentiator

Problem solved

Functional benefit

Products and services

• RZL-012 (Utenpanium/Tapencarium) RZL-012 (also known as Utenpanium or Tapencarium) is Raziel's proprietary fat-dissolving injectable compound designed as a single-session, non-surgical therapy for focal fat reduction. It is the platform molecule underlying all of Raziel's clinical programs and applicable to both aesthetic and therapeutic indications.
• Submental Fat (SMF) Treatment Non-surgical injectable treatment for reduction of submental fat (double chin) using RZL-012, intended for adult aesthetic patients seeking focal fat reduction without surgery. Currently in Phase 3 registration trial in China via the Fosun Pharma licensing partnership and at FDA End of Phase 2 stage in the US.
• Body Contouring (Flanks) Treatment Non-surgical injectable treatment for body contouring targeting flank fat using RZL-012. Proof-of-concept clinical study has been completed, with results presented at ISAPS 2023 and a manuscript submitted to Aesthetic Surgery Journal Open Forum.
• Dercum's Disease Treatment Therapeutic application of RZL-012 for the treatment of Dercum's Disease, a rare condition characterized by painful lipomas (benign fatty tumors). Clinical results have been published in the peer-reviewed journal Dermatologic Surgery.

Quantifiable outcome

• 17% annual organic growth achieved by leadership team at Allergan Aesthetic business (reference to team experience)

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Fosun Pharma (via JuveStar)coreChannel Partner/ Reseller/ Distributor · 1 January 2024Raziel signed a commercial licensing agreement with Fosun Pharma (through its JuveStar affiliate) for the Chinese market. This partnership covers the submental fat (double chin) indication and includes a Phase 3 registration trial initiated in China. The agreement grants Fosun Pharma distribution rights for RZL-012 in China.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• AbbVie (Allergan Aesthetics): Owns Kybella, the only FDA-approved injectable for submental fat reduction, as well as Botox Cosmetic and the Juvederm franchise. Direct incumbent competitor to Raziel in injectable focal fat reduction with established physician relationships, training, and commercial scale.
• Galderma: Global leader in aesthetic dermatology with the Sculptra, Restylane, and Dysport franchises. Comparable as an aesthetics-focused injectable platform with overlapping physician customer base and similar regulatory/commercial pathway for new injectable assets.
• Merz Aesthetics: Markets Xeomin, Radiesse, Belotero, and Ultherapy in medical aesthetics. Comparable broad incumbent in injectable aesthetics with similar physician channel and complementary approach to facial rejuvenation that overlaps with Raziel's target use cases.
• Bausch Health / Solta Medical: Solta markets Thermage, CoolSculpting, and other body-contouring/energy-based devices that compete for the same aesthetic patient demand for non-surgical fat reduction. Comparable as an incumbent in non-surgical body contouring using a different modality but addressing overlapping patient needs.

Direct peers

• Revance Therapeutics: Aesthetic-focused biopharma that developed and launched Daxxify (a long-acting neuromodulator). Directly comparable as a smaller, science-driven aesthetics company pursuing FDA approval and commercial launch of an injectable aesthetic product via a specialty sales channel.
• Evolus: Aesthetic injectable company that launched Jeuveau (a botulinum toxin) competing directly with Botox in the US. Closely comparable specialty aesthetics commercial-stage company with a similar lean operating model and focus on the same physician customer base Raziel targets.

Emerging players

• Suneva Medical: Regenerative aesthetics company behind Bellafill and the Puregraft fat-grafting system. Comparable as an emerging aesthetics platform with injectable and fat-related products addressing body contouring and facial rejuvenation, partially overlapping with Raziel's focal fat indication set.
• Hugel: South Korean aesthetics company with botulinum toxin (Botulax), hyaluronic acid fillers, and a regional licensing-led commercial model. Comparable for its injectable aesthetics portfolio and Asian-market licensing strategy, paralleling Raziel's Fosun partnership approach.
• Croma-Pharma: European aesthetics specialist focused on hyaluronic acid fillers (Princess range), PRP, and biostimulators. Comparable as a privately held, specialty aesthetics injectable player pursuing multi-country licensing distribution for new aesthetic products.
• Sinclair Pharma: Aesthetic medicine company with Ellansé, MaiLi, and Perfectha injectable franchises. Comparable as a focused injectable aesthetics business built around regional licensing partnerships for new aesthetic products in similar submental and facial rejuvenation indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=AcKEPiFnx9g&feature=youtu.be
• LinkedInlinkedin.com/company/raziel-therapeutics
• Instagraminstagram.com/thetechnologyofbeauty/p/DI4OhFHxSkZ

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Raziel Therapeutics